Despite only being discovered about 25 years ago, VHHs have garnered increasing attention due to their unique properties such as smaller size, increased stability, and ease of production compared to traditional antibodies. Several VHH-based drugs have reached clinical approval, primarily in oncology and immunology including:
References
® Nanobody is a trademark of Ablynx.